Hormone Targets for the Treatment of Sleep Disorders in Postmenopausal Women with Schizophrenia

While the early identification of insomnia in patients with schizophrenia is of clinical relevance, the use of specific compounds to treat insomnia has been studied less in postmenopausal women with schizophrenia. We aimed to explore the effects of melatonin, sex hormones, and raloxifene for the tre...

Full description

Bibliographic Details
Authors: González-Rodríguez, Alexandre|||0000-0003-1855-8566, Haba-Rubio, José, Usall, Judith|||0000-0002-1746-7737, Natividad, Mentxu, Soria, Virginia|||0000-0001-6412-6831, Labad, Javier|||0000-0003-2214-1886, Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
Format: article
Publication Date:2022
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:257286
Online Access:https://ddd.uab.cat/record/257286
https://dx.doi.org/urn:doi:10.3390/clockssleep4010007
Access Level:Open access
Keyword:Schizophrenia
Delusional disorder
Sleep
Insomnia
Treatment
Description
Summary:While the early identification of insomnia in patients with schizophrenia is of clinical relevance, the use of specific compounds to treat insomnia has been studied less in postmenopausal women with schizophrenia. We aimed to explore the effects of melatonin, sex hormones, and raloxifene for the treatment of insomnia in these populations. Although melatonin treatment improved the quality and efficiency of the sleep of patients with schizophrenia, few studies have explored its use in postmenopausal women with schizophrenia. The estrogen and progesterone pathways are dysregulated in major psychiatric disorders, such as in schizophrenia. While, in the context of menopause, a high testosterone-to-estradiol ratio is associated with higher frequencies of depressive symptoms, the effects of estradiol and other sex hormones on sleep disorders in postmenopausal women with schizophrenia has not been sufficiently investigated. Raloxifene, a selective estrogen receptor modulator, has shown positive effects on sleep disorders in postmenopausal women. Future studies should investigate the effectiveness of hormonal compounds on insomnia in postmenopausal women with schizophrenia.